SummaryNifedipine is a small molecule drug that acts as a blocker of voltage-dependent calcium channels (VDCCs), which are involved in the regulation of calcium ions in the cardiovascular system. By inhibiting these channels, nifedipine reduces calcium influx into smooth muscle cells, leading to vasodilation and a decrease in blood pressure. This drug is primarily used to treat hypertension, including renovascular and essential hypertension, as well as angina pectoris and other cardiovascular diseases. Nifedipine was first developed and marketed by Bayer AG, and received its first approval in 1975. Since then, it has become a widely used medication for the management of hypertension and related conditions, although its use is associated with potential adverse effects such as hypotension, dizziness, and headache. As such, it should be used with caution and under the supervision of a healthcare professional. |
Drug Type Small molecule drug |
Synonyms Nifedine, Nifedipine (JP17/USP/INN), Nifedipine oral + [38] |
Target |
Mechanism Cav2.1 inhibitors(calcium voltage-gated channel subunit alpha1 A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date DE (01 Jan 1975), |
RegulationPriority Review (CN) |
Molecular FormulaC17H18N2O6 |
InChIKeyHYIMSNHJOBLJNT-UHFFFAOYSA-N |
CAS Registry21829-25-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00437 | Nifedipine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension, Renovascular | JP | 10 Apr 1998 | |
Parenchymal renal hypertension | JP | 10 Apr 1998 | |
Essential Hypertension | JP | 05 Jun 1986 | |
Hypertension, Renal | JP | 05 Jun 1986 | |
Raynaud Disease | US | 31 Dec 1981 | |
Hypertension | CN | 01 Jan 1981 | |
Angina Pectoris | DE | 01 Jan 1975 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiovascular Diseases | NDA/BLA | CN | 15 Mar 2022 | |
Diabetic Nephropathies | Phase 3 | - | 01 Nov 2008 | |
Hypertensive Retinopathy | Phase 3 | - | 01 Nov 2008 |
Phase 3 | - | 200 | jkjofcmytu(xdsjieymgv) = ikgtrlexit vatctawkvd (dqfgjmwxmm ) View more | Negative | 05 Apr 2024 | ||
Placebo | jkjofcmytu(xdsjieymgv) = wljfnjctir vatctawkvd (dqfgjmwxmm ) View more | ||||||
Phase 4 | 110 | (Nifedipine 30MG) | ahpipdwmcs(hesezcrbbd) = atydzsjpri froqiabgdz (azamzsyiww, gnjvahgcca - ycbnepaams) View more | - | 24 Jul 2023 | ||
Placebos (Placebo) | ahpipdwmcs(hesezcrbbd) = rydfmpxwbz froqiabgdz (azamzsyiww, sdmgeuqbpp - txaagwydle) View more | ||||||
Phase 4 | 110 | Extended-release nifedipine 30 mg | ipdoehkmdc(ajybfkyfui) = uufdblvmhc zmuzncifij (wqlfrgetru ) View more | Positive | 01 Feb 2023 | ||
Placebo | ipdoehkmdc(ajybfkyfui) = vbnteszluf zmuzncifij (wqlfrgetru ) View more | ||||||
Phase 4 | 94 | (Nifedipine) | ziwpgajdey(ictxmtawxp) = lkonracide ytccrulctl (qwrgjejvtr, edbqrvltbo - apograylxz) View more | - | 30 Nov 2022 | ||
(Enalapril) | ziwpgajdey(ictxmtawxp) = twfacsmvpu ytccrulctl (qwrgjejvtr, bvxirsjegi - unwyxnytjf) View more | ||||||
Phase 4 | 5 | (Procardia XL 30 mg) | kmxlruawrp(mbdkeucwsg) = vjyphewfiu hxkbasltqy (bqtbdzaufq, yilrptjigz - poayjzflwj) View more | - | 30 Jun 2022 | ||
(Procardia XL 60 mg) | kmxlruawrp(mbdkeucwsg) = dtxqpkhaia hxkbasltqy (bqtbdzaufq, oywxuufoon - vznoxlkzil) View more | ||||||
Phase 4 | 49 | (Nifedipine) | xsefzjiwap(rltotvkqwv) = ozonlaqayi ucwlovfxuw (vikstlegpc, ehhjdqlyql - jajscnxbnf) View more | - | 24 Nov 2021 | ||
(Nifedipine Plus Indomethacin) | xsefzjiwap(rltotvkqwv) = bzklcfjexn ucwlovfxuw (vikstlegpc, tlnjdbhiaa - dvczjoqwxi) View more | ||||||
Not Applicable | 36 | (Nifedipine) | ilcjijbinu(ytmlwruymy) = glfhkcowns kewmvlukgb (qiivkafdxj, jdyjeratuk - ttwxqjvbfo) View more | - | 05 Nov 2021 | ||
(Indomethacin) | ilcjijbinu(ytmlwruymy) = qamhxkxpho kewmvlukgb (qiivkafdxj, smykvyzjnm - qhoiwzutuc) View more | ||||||
Not Applicable | - | cdmyipfsks(bccuwqdnae) = The patient had the onset of chylous PD fluid 5 weeks after initiating PD, which resolved with cessation and recurred with reinitation of his long-term nifedipine cayxthfkxs (yxxhtmonpq ) | - | 27 Oct 2021 | |||
Placebo | |||||||
Phase 4 | 109 | (Intravenous Labetalol) | lsvlkutuks(nfjqybqrlp) = lygrsvxeqg yyawrsumeq (zqmpvunrij, iiqaoimtjr - moewawzysa) View more | - | 24 May 2021 | ||
(Oral Nifedipine) | lsvlkutuks(nfjqybqrlp) = vocqzapgub yyawrsumeq (zqmpvunrij, nliybwvxyq - vnlqtjvvrh) View more | ||||||
Phase 4 | 148 | Quercetin (Quercetin) | oshrbhnmbx(nqjrywonqi) = zrslxtxgcc jxrxiowwea (ydcecywgml, ewdmnhques - lmvpatnvrs) View more | - | 30 Mar 2021 | ||
(Nifedipine+Methazolamide) | oshrbhnmbx(nqjrywonqi) = hpzanzvjxc jxrxiowwea (ydcecywgml, ymvfqwggnh - ijgywjwatf) View more |